JPS6025929A - カプセル化細胞、その製造方法および用途 - Google Patents
カプセル化細胞、その製造方法および用途Info
- Publication number
- JPS6025929A JPS6025929A JP58131097A JP13109783A JPS6025929A JP S6025929 A JPS6025929 A JP S6025929A JP 58131097 A JP58131097 A JP 58131097A JP 13109783 A JP13109783 A JP 13109783A JP S6025929 A JPS6025929 A JP S6025929A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- composition
- protein
- wall
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title description 11
- 210000004027 cell Anatomy 0.000 claims description 119
- 238000000034 method Methods 0.000 claims description 62
- 239000002775 capsule Substances 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 239000003431 cross linking reagent Substances 0.000 claims description 26
- 239000012528 membrane Substances 0.000 claims description 24
- 235000018102 proteins Nutrition 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 20
- 238000012545 processing Methods 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 18
- 239000011148 porous material Substances 0.000 claims description 16
- 108090000790 Enzymes Proteins 0.000 claims description 15
- 102000004190 Enzymes Human genes 0.000 claims description 15
- 229940088598 enzyme Drugs 0.000 claims description 15
- 238000004132 cross linking Methods 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 108060003951 Immunoglobulin Proteins 0.000 claims description 9
- -1 colladan Proteins 0.000 claims description 9
- 102000018358 immunoglobulin Human genes 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 235000015097 nutrients Nutrition 0.000 claims description 8
- 239000008159 sesame oil Substances 0.000 claims description 8
- 235000011803 sesame oil Nutrition 0.000 claims description 8
- 108010088751 Albumins Proteins 0.000 claims description 7
- 102000009027 Albumins Human genes 0.000 claims description 7
- 230000000593 degrading effect Effects 0.000 claims description 7
- 244000005700 microbiome Species 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 6
- 241000196324 Embryophyta Species 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 235000010446 mineral oil Nutrition 0.000 claims description 4
- 239000002480 mineral oil Substances 0.000 claims description 4
- 206010003445 Ascites Diseases 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 108010068370 Glutens Proteins 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000005018 casein Substances 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 235000021312 gluten Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000004382 Amylase Substances 0.000 claims description 2
- 108010065511 Amylases Proteins 0.000 claims description 2
- 102000013142 Amylases Human genes 0.000 claims description 2
- 108010076119 Caseins Proteins 0.000 claims description 2
- 108010059892 Cellulase Proteins 0.000 claims description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000019483 Peanut oil Nutrition 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 102000035195 Peptidases Human genes 0.000 claims description 2
- 102000006382 Ribonucleases Human genes 0.000 claims description 2
- 108010083644 Ribonucleases Proteins 0.000 claims description 2
- 235000019418 amylase Nutrition 0.000 claims description 2
- 229940106157 cellulase Drugs 0.000 claims description 2
- 235000012343 cottonseed oil Nutrition 0.000 claims description 2
- 239000002385 cottonseed oil Substances 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 108010059345 keratinase Proteins 0.000 claims description 2
- 239000000312 peanut oil Substances 0.000 claims description 2
- 235000018553 tannin Nutrition 0.000 claims description 2
- 229920001864 tannin Polymers 0.000 claims description 2
- 239000001648 tannin Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 108010077805 Bacterial Proteins Proteins 0.000 claims 6
- 210000002784 stomach Anatomy 0.000 claims 4
- 239000000592 Artificial Cell Substances 0.000 claims 3
- 108020000946 Bacterial DNA Proteins 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000011632 Caseins Human genes 0.000 claims 1
- 108010073771 Soybean Proteins Proteins 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 230000001902 propagating effect Effects 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- 229940001941 soy protein Drugs 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
- 210000002845 virion Anatomy 0.000 claims 1
- 239000002609 medium Substances 0.000 description 33
- 239000003094 microcapsule Substances 0.000 description 20
- 239000012071 phase Substances 0.000 description 15
- 239000000463 material Substances 0.000 description 11
- 239000013543 active substance Substances 0.000 description 10
- 239000006185 dispersion Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000005538 encapsulation Methods 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- WMPOZLHMGVKUEJ-UHFFFAOYSA-N decanedioyl dichloride Chemical compound ClC(=O)CCCCCCCCC(Cl)=O WMPOZLHMGVKUEJ-UHFFFAOYSA-N 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000011257 shell material Substances 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000007963 capsule composition Substances 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 229920000151 polyglycol Polymers 0.000 description 3
- 239000010695 polyglycol Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 241000120694 Thestor Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- PWAXUOGZOSVGBO-UHFFFAOYSA-N adipoyl chloride Chemical group ClC(=O)CCCCC(Cl)=O PWAXUOGZOSVGBO-UHFFFAOYSA-N 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 231100001223 noncarcinogenic Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012899 standard injection Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Landscapes
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58131097A JPS6025929A (ja) | 1983-07-20 | 1983-07-20 | カプセル化細胞、その製造方法および用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58131097A JPS6025929A (ja) | 1983-07-20 | 1983-07-20 | カプセル化細胞、その製造方法および用途 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3287274A Division JPH0685711B2 (ja) | 1991-10-08 | 1991-10-08 | 細胞の繁殖方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6025929A true JPS6025929A (ja) | 1985-02-08 |
JPH048034B2 JPH048034B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1992-02-13 |
Family
ID=15049904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP58131097A Granted JPS6025929A (ja) | 1983-07-20 | 1983-07-20 | カプセル化細胞、その製造方法および用途 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS6025929A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009013182A (ja) * | 1996-12-23 | 2009-01-22 | Bavarian Nordic As | 抗体を産生するカプセル封入細胞 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55157502A (en) * | 1979-03-28 | 1980-12-08 | Damon Corp | Live tissue encapsulation and tissue transplantation |
JPS57202289A (en) * | 1981-03-13 | 1982-12-11 | Damon Corp | Culturing of uncourage dependent cell |
JPS5816693A (ja) * | 1981-03-13 | 1983-01-31 | デイモン・バイオテック・インコ−ポレ−テッド | 細胞により産生される物質の製造方法 |
-
1983
- 1983-07-20 JP JP58131097A patent/JPS6025929A/ja active Granted
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55157502A (en) * | 1979-03-28 | 1980-12-08 | Damon Corp | Live tissue encapsulation and tissue transplantation |
JPS57202289A (en) * | 1981-03-13 | 1982-12-11 | Damon Corp | Culturing of uncourage dependent cell |
JPS5816693A (ja) * | 1981-03-13 | 1983-01-31 | デイモン・バイオテック・インコ−ポレ−テッド | 細胞により産生される物質の製造方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009013182A (ja) * | 1996-12-23 | 2009-01-22 | Bavarian Nordic As | 抗体を産生するカプセル封入細胞 |
Also Published As
Publication number | Publication date |
---|---|
JPH048034B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1992-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4798786A (en) | Living cells encapsulated in crosslinked protein | |
US5691060A (en) | Utilization of a transacylation reaction between an esterified polysaccharide and a polyaminated or polyhydroxylated substance for fabricating microparticles, microparticles thus obtained, methods and compositions containing them | |
US4352883A (en) | Encapsulation of biological material | |
US4391909A (en) | Microcapsules containing viable tissue cells | |
CA1174600A (en) | Encapsulation of live animal cells | |
JP3524096B2 (ja) | 水性媒体において膜をゲル化粒子の少なくとも表面に形成するためのエステル化多糖とポリアミンとの間のアシル交換反応の使用、それにより生成した粒子、それらの製造方法及び前記粒子を含有する組成物 | |
US4532123A (en) | Dual Microcapsules and process for their preparation | |
JPS6244919B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
US5470731A (en) | Coated transplant and method for making same | |
CN103619911B (zh) | 交联的聚‑e‑赖氨酸非颗粒状支持物 | |
JPS58500063A (ja) | ペレット、微小ビ−ド、微小カプセルおよびそれらの製法 | |
EP0102391A1 (en) | Dual microcapsules | |
EP0129619B1 (en) | Encapsulated cells, their method of preparation and use | |
GB2094832A (en) | Process for culturing anchorage dependent cells | |
Sakai et al. | Control of molecular weight cut-off for immunoisolation by multilayering glycol chitosan-alginate polyion complex on alginate-based microcapsules | |
Lu et al. | Cell encapsulation with alginate and α‐phenoxycinnamylidene‐acetylated poly (allylamine) | |
WO2016065279A1 (en) | A capsule for the oral administration of biopharmaceuticals | |
JPS6025929A (ja) | カプセル化細胞、その製造方法および用途 | |
Chang et al. | Artificial cells for bioencapsulation of cells and genetically engineered E. coli: for cell therapy, gene therapy, and removal of urea and ammonia | |
US12194154B2 (en) | Method for producing hydrogel microcapsules, kit for producing capsules, and use therefor | |
US2118117A (en) | Method for separating constituents of biologically valuable starting materials | |
CA1214389A (en) | Encapsulated cells, their method of preparation and use | |
JPH05176754A (ja) | 細胞の繁殖方法 | |
GB2119734A (en) | Encapsulated living tissue | |
GB2119737A (en) | Encapsulation of viable tissue |